6-(4-fluorophenyl)hexan-1-ol | 128577-65-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-(4-fluorophenyl)hexan-1-ol
• 英文别名: 4-fluorophenylhexylalcohol
• CAS: 128577-65-1
• 化学式: C₁₂H₁₇FO
• 分子量: 196.265
• InChiKey: KUUBEWQULDTAIL-UHFFFAOYSA-N

物化性质

• 沸点：
  297.5±23.0 °C(Predicted)
• 密度：
  1.032±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-(4-fluorophenyl)hexan-1-ol 在 N-溴代丁二酰亚胺(NBS) 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 6-(4-fluorophenoxy)hexyl bromide
  参考文献：
  名称：

  COMPOUNDS AND MESOGENIC MEDIA

  摘要：

  公开的是公式I的化合物在液晶介质中的使用，特别是包含该液晶介质的柔性电液晶器件。

  公开号：

  US20160229795A1
• 作为产物：
  描述：

  4-羧丁基三苯基溴化膦 在 palladium on activated charcoal lithium aluminium tetrahydride 、 氢气 、 lithium hexamethyldisilazane 作用下， 以 乙醚 、 乙酸乙酯 为溶剂， 25.0 ℃ 、206.84 kPa 条件下， 反应 8.0h， 生成 6-(4-fluorophenyl)hexan-1-ol
  参考文献：
  名称：

  Benzophenone dicarboxylic acid antagonists of leukotriene B4. 2. Structure-activity relationships of the lipophilic side chain

  摘要：

  A series of lipophilic benzophenone dicarboxylic acid derivatives were found to inhibit the binding of the potent chemotaxin leukotriene B4 (LTB4) to its receptor on intact human neutrophils. Activity at the LTB4 receptor was determined by using a [3H]LTB4-binding assay. The structure-activity relationship for the lipophilic side chain was systematically investigated. Compounds with n-alkyl side chains of varying lengths were prepared and tested. Best inhibition of [3H]LTB4 binding was observed with the n-decyl derivative. Analogues with alkyl chains terminated with an aromatic ring showed improved activity. The 6-phenylhexyl side chain was optimal. Substitution on the terminal aromatic ring was also evaluated. Methoxyl, methylsulfinyl, and methyl substituents greatly enhanced the activity of the compound. For a given substituent, the para isomer had the best activity. Thus the nature of the lipophilic side chain can greatly influence the ability of the compounds to inhibit the binding of LTB4 to its receptor on intact human neutrophils. The most active compound from this series, 84 (LY223982), bound to the LTB4 receptor with an affinity approaching that of the agonist.

  DOI：

  10.1021/jm00172a020

文献信息

• [EN] TETRAZOLINONE COMPOUNDS AND ITS USE<br/>[FR] COMPOSÉS DE TÉTRAZOLINONE ET LEUR UTILISATION
  申请人：SUMITOMO CHEMICAL CO

  公开号：WO2013162077A1

  公开（公告）日：2013-10-31

  The present invention provides a compound having an excellent efficacy for controlling pests. A tetrazolinone compound of a formula (1): [wherein, R1 represents an C6-C16 aryl group, an C1-C12 alkyl group, a C3-C12 cycloalkyl group or an adamantyl group, etc., which each optionally be substituted; R2 represents a hydrogen atom, an C1-C12 alkyl group, or a halogen atom, etc.; R4 and R5 represent independently of each other a hydrogen atom or an C1-C3 alkyl group, etc.; R6, R7, R8 and R9 represent independently of each other a hydrogen atom, a halogen atom, an C1-C12 alkyl group, a C1-C12 haloalkyl group, an C2-C12 alkenyl group, a C3-C12 cycloalkyl group, an C1-C12 alkoxy group or a C1-C12 haloalkoxy group, etc.; X and Y represent independently of each other a sulfur atom or an oxygen atom; Q represents an oxygen atom or a sulfur atom; and R10 represents an C1-C6 alkyl group, etc.] shows an excellent controlling efficacy on pests.

  本发明提供了一种具有优异杀虫效果的化合物。式（1）中的四氮杂酮化合物：[其中，R1代表一个C6-C16芳基，一个C1-C12烷基，一个C3-C12环烷基或一个金刚烷基等，每个都可以选择性地被取代；R2代表一个氢原子，一个C1-C12烷基或一个卤素原子等；R4和R5分别独立地代表一个氢原子或一个C1-C3烷基等；R6、R7、R8和R9分别独立地代表一个氢原子，一个卤素原子，一个C1-C12烷基，一个C1-C12卤代烷基，一个C2-C12烯基，一个C3-C12环烷基，一个C1-C12烷氧基或一个C1-C12卤代烷氧基等；X和Y分别独立地代表一个硫原子或一个氧原子；Q代表一个氧原子或一个硫原子；R10代表一个C1-C6烷基等]对害虫有极佳的控制效果。
• Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity
  作者：Md Ashraf-Uz-Zaman、Md Sanaullah Sajib、Luca Cucullo、Constantinos M. Mikelis、Nadezhda A. German

  DOI：10.1016/j.bmcl.2018.10.036

  日期：2018.12

  as a chemotherapeutic agent. In vivo experiments have confirmed the cytotoxic activity of penfluridol in triple-negative breast cancer model, lung cancer model, and further studies have been proposed to assess its anticancer activity and viability for the treatment of glioblastomas. However, penfluridol anticancer activity was observed at a dosage significantly higher than that administered in antipsychotic

  最近的几份报告强调了使用众所周知的抗精神病药物五氟利多作为化疗药物的可行性。体内实验已经证实了五氟利多在三阴性乳腺癌模型、肺癌模型中的细胞毒活性，并且已经提出进一步的研究来评估其抗癌活性和治疗胶质母细胞瘤的可行性。然而，在剂量显着高于抗精神病药物治疗的剂量下观察到五氟利多的抗癌活性，因此引发了对接受强化药物治疗的患者可能出现中枢神经系统副作用的担忧。在这项研究中，我们与一组类似物并排评估了五氟利多的潜在 CNS 毒性。
• Azetidinone derivatives for the treatment of atherosclerosis
  申请人：SmithKline Beecham p.l.c.

  公开号：US06071899A1

  公开（公告）日：2000-06-06

  Azetidinone derivatives of formula (I) in which R.sup.1 and R.sup.2, which may be the same or different, is each selected from hydrogen or C.sub.(1-8) alkyl; R.sup.3 is C.sub.(1-8) alkyl or C.sub.(3-8) cycloalkyl each of which may be optionally substituted; X is a linker group; Y is an aryl group; and n is 0, 1 or 2; and excluding benzyl (4-methylthio-2-oxo-azetidin-1-yl)acetate are inhibitors of the enzyme Lp PLA2 and are of use in therapy, in particular treating atherosclerosis.

  式(I)的Azetidinone衍生物中，R.sup.1和R.sup.2，可以相同也可以不同，均选择自氢或C.sub.(1-8)烷基；R.sup.3是C.sub.(1-8)烷基或C.sub.(3-8)环烷基，可以选择性地被取代；X是连接基；Y是芳基基团；n为0、1或2；但不包括苄基(4-甲硫基-2-氧代-氮杂环戊酸-1-基)醋酸酯。这些衍生物是Lp PLA2酶的抑制剂，可用于治疗，特别是用于治疗动脉粥样硬化。
• CHEMICAL COMPOUNDS
  申请人：Evindar Ghotas

  公开号：US20100009936A1

  公开（公告）日：2010-01-14

  The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immuno-suppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.

  该发明提供了化合物I的公式，其制备方法，以及它们作为药物活性的免疫抑制剂用于治疗自身免疫性疾病，器官移植排斥，与激活的免疫系统相关的疾病，以及其他淋巴减少或SIP受体调节的疾病。
• Chemical compounds
  申请人：Evindar Ghotas

  公开号：US20080096938A1

  公开（公告）日：2008-04-24

  The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or S1P receptors.

  本发明提供了化合物I的公式、其制备方法以及其作为药物活性的免疫抑制剂，用于治疗自身免疫性疾病、器官移植排斥、与激活的免疫系统相关的疾病，以及其他受淋巴细胞减少或S1P受体调节的疾病。